Market News / Story
Pulse Biosciences hits 164-patient enrollment target in NANOPULSE-AF pivotal IDE study
·
Pulse Biosciences achieved its NANOPULSE-AF enrollment target of 164 evaluable patients across 15 sites. Key Highlights: Study reached target enrollment of 164 evaluable participants across 15 clinical sites for the nPulse Cardiac Catheter System. First patients treated in April 2026; primary safety and effectiveness endpoints to be assessed at 6 and 12 months post-ablation. NANOPULSE-AF is a prospective, multicenter, non-randomized IDE pivotal study in drug-resistant,…